Vaxcyte (PCVX) Stock: Buy, Sell, or Hold?
PCVX - Vaxcyte, Inc. Common Stock
$59.47
0.57 (0.97%)
â˛
5d:
-2.78%
30d:
-0.3%
90d:
+25.76%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 03, 2026
Smart Money Distribution
Options positioning is turning defensive after a sharp run-up - a pattern consistent with institutional profit-taking. View Scanner →
Signal fired Sep 3, 2026 at $61.17 · last confirmed Sep 10, 2026
Strength: 6.2/10
Get Alerted When PCVX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: PCVX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: PCVX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: PCVX is currently trading at $59.47, which is considered fair relative to its 30-day fair value range of $57.56 to $61.84.
Technical Outlook: Technically, PCVX is in a uptrend. The price is currently testing key support at $58.21. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: PCVX scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $109.00 (+83.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PCVX is in a uptrend. The price is currently testing key support at $58.21. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: PCVX scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $109.00 (+83.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$57.56 -
$61.84
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 83.3% below Wall St target ($109.00)
- WARNING: Composite score 45/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$57.56 -
$61.84
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$58.21
Resistance Level
$62.90
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-8.24
Wall Street Target
$109.00
(+83.3%)
Share & Embed Analysis
Last updated: September 12, 2026 5:03 AM ET
Data refreshes hourly during market hours. Next update: 6:03 AM
Data refreshes hourly during market hours. Next update: 6:03 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PCVX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Elvia Cowan
SELL
3000 shares
2026-04-07
Elvia Cowan
SELL
1892 shares
2026-03-17
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
29 analysts |
$91 | 58 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 56 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 45 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 60 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 57 HOLD |
